Germline variants in IKZF1, ARID5B, and CEBPE as risk factors for adult-onset acute lymphoblastic leukemia: an analysis from the GMALL study group

Por Burmeister, Thomas, Bartels, Gesine, Gröger, Daniela, Trautmann, Heiko, Schwartz, Stefan, Lenz, Klaus, Tietze-Bürger, Carola, Viardot, Andreas, Wäsch, Ralph, Horst, Heinz-August, Reinhardt, Richard, Gökbuget, Nicola, Hoelzer, Dieter, Kneba, Michael, Brüggemann, Monika
Publicado em 2014

Calculation of Direct Antiretroviral Treatment Costs and Potential Cost Savings by Using Generics in the German HIV ClinSurv Cohort

Por Stoll, Matthias, Kollan, Christian, Bergmann, Frank, Bogner, Johannes, Faetkenheuer, Gerd, Fritzsche, Carlos, Hoeper, Kirsten, Horst, Heinz-August, van Lunzen, Jan, Plettenberg, Andreas, Reuter, Stefan, Rockstroh, Jürgen, Stellbrink, Hans-Jürgen, Hamouda, Osamah, Bartmeyer, Barbara
Publicado em 2011

From pills to patients: an evaluation of data sources to determine the number of people living with HIV who are receiving antiretroviral therapy in Germany

Por Schmidt, Daniel, Kollan, Christian, Stoll, Matthias, Stellbrink, Hans-Jürgen, Plettenberg, Andreas, Fätkenheuer, Gerd, Bergmann, Frank, Bogner, Johannes R, van Lunzen, Jan, Rockstroh, Jürgen, Esser, Stefan, Jensen, Björn-Erik Ole, Horst, Heinz-August, Fritzsche, Carlos, Kühne, Andrea, an der Heiden, Matthias, Hamouda, Osamah, Bartmeyer, Barbara
Publicado no BMC Public Health (2015)

Improved outcome of adult Burkitt lymphoma/leukemia with rituximab and chemotherapy: report of a large prospective multicenter trial

Por Hoelzer, Dieter, Walewski, Jan, Döhner, Hartmut, Viardot, Andreas, Hiddemann, Wolfgang, Spiekermann, Karsten, Serve, Hubert, Dührsen, Ulrich, Hüttmann, Andreas, Thiel, Eckhard, Dengler, Jolanta, Kneba, Michael, Schaich, Markus, Schmidt-Wolf, Ingo G. H., Beck, Joachim, Hertenstein, Bernd, Reichle, Albrecht, Domanska-Czyz, Katarzyna, Fietkau, Rainer, Horst, Heinz-August, Rieder, Harald, Schwartz, Stefan, Burmeister, Thomas, Gökbuget, Nicola
Publicado no Blood (2014)

Vosaroxin plus cytarabine versus placebo plus cytarabine in patients with first relapsed or refractory acute myeloid leukaemia (VALOR): a randomised, controlled, double-blind, mult...

Por Ravandi, Farhad, Ritchie, Ellen K., Sayar, Hamid, Lancet, Jeffrey E., Craig, Michael D., Vey, Norbert, Strickland, Stephen A., Schiller, Gary J., Jabbour, Elias, Erba, Harry P., Pigneux, Arnaud, Horst, Heinz-August, Recher, Christian, Klimek, Virginia M., Cortes, Jorge, Roboz, Gail J., Odenike, Olatoyosi, Thomas, Xavier, Havelange, Violaine, Maertens, Johan, Derigs, Hans-Günter, Heuser, Michael, Damon, Lloyd, Powell, Bayard L., Gaidano, Gianluca, Carella, Angelo-Michele, Wei, Andrew, Hogge, Donna, Craig, Adam R., Fox, Judith A., Ward, Renee, Smith, Jennifer A., Acton, Gary, Mehta, Cyrus, Stuart, Robert K., Kantarjian, Hagop M.
Publicado no Lancet Oncol (2015)